1-Acetyl-3-(3-chloro-benzoyl)-piperidin-4-one | 148363-35-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Acetyl-3-(3-chloro-benzoyl)-piperidin-4-one
• 英文别名: 1-Acetyl-3-(3-chlorobenzoyl)piperidin-4-one
• CAS: 148363-35-3
• 化学式: C₁₄H₁₄ClNO₃
• 分子量: 279.723
• InChiKey: IYAVPGRNFIAQQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-Acetyl-3-(3-chloro-benzoyl)-piperidin-4-one 在 sodium ethanolate 作用下， 以 乙醇 、 苯 为溶剂， 反应 10.0h， 生成 1-[2-Amino-4-(3-chloro-phenyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-ethanone
  参考文献：
  名称：

  Novel tetrahydropyrido[4,3-d]pyrimidines as gastric antilesion agents

  摘要：

  A variety of substituted tetrahydropyrido[4,3-d]pyrimidines was prepared and found to possess gastric antilesion against ethanol-induced lesions in rats. The more potent compounds possessed similar activity against aspirin-induced gastric lesions. A selective group of compounds was determined to be inactive as gastric antisecretory agents in rabbit isolated parietal cells. The antilesion properties of these tetrahydropyrido[4,3-d]pyrimidines make them a potential alternative to prostaglandin therapy for gastric antilesion therapy and may have clinical utility in peptic ulcer disease.

  DOI：

  10.1016/0223-5234(92)90085-f
• 作为产物：
  描述：

  N-乙酰基-4-哌啶酮 在 对甲苯磺酸 、 三乙胺 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 28.0h， 生成 1-Acetyl-3-(3-chloro-benzoyl)-piperidin-4-one
  参考文献：
  名称：

  Synthesis, in vitro [3H]prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a new class of antihypertensive agents

  摘要：

  A series of new 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines was synthesized and screened for in vitro [3H]prazosin displacement activity. The results correlated well with their antihypertensive activity in spontaneous hypertensive rats. 1-Benzyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyrid ine (50, L 16052) was selected for further pharmacological evaluations of its potency when administered orally to conscious renal hypertensive dogs.

  DOI：

  10.1021/jm00145a015

文献信息

• Farnesyltransferase inhibitors
  申请人：——

  公开号：US20030199544A1

  公开（公告）日：2003-10-23

  Compounds having the formula 1 are farnesyltransferase inhibitors. Also disclosed are methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds.

  具有化学式1的化合物是法尼基转移酶抑制剂。还公开了制备这些化合物的方法、含有这些化合物的药物组合物，以及使用这些化合物进行治疗的方法。
• Carbamic acid esters as inhibitors of factor xa
  申请人：——

  公开号：US20030199698A1

  公开（公告）日：2003-10-23

  Novel compounds of the formula I 1 in which R, R 1 and R 2 are as defined in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic illnesses.

  公式I1中的新化合物，其中R、R1和R2如专利申请1中定义的那样，是凝血因子Xa的抑制剂，可用于预防和/或治疗血栓性疾病。